Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
Authors:
- Emilia MontagnaEMEmilia Montagna
- Giuseppe CancelloGCGiuseppe Cancello
- Vincenzo BagnardiVBVincenzo Bagnardi
- Davide PastrelloDPDavide Pastrello
- Silvia DellapasquaSDSilvia Dellapasqua
- Gino PerriGPGino Perri
- Giuseppe VialeGVGiuseppe Viale
- Paolo VeronesiPVPaolo Veronesi
- Alberto LuiniALAlberto Luini
- Mattia IntraMIMattia Intra
- Angelica CalleriACAngelica Calleri
- Cristiano RampinelliCRCristiano Rampinelli
- 1 June 2012
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 12 (3) , 207-214
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast CancerJournal of Clinical Oncology, 2011
- Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus BevacizumabClinical Cancer Research, 2009
- Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural AnalysesClinical Cancer Research, 2008
- A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast CancerClinical Cancer Research, 2008
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast CancerJournal of Clinical Oncology, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Serum EGFR and serum HER‐2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapyCancer, 2007
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993